204 related articles for article (PubMed ID: 33376543)
21. Immune response to C. novyi-NT immunotherapy.
DeClue AE; Axiak-Bechtel SM; Zhang Y; Saha S; Zhang L; Tung D; Bryan JN
Vet Res; 2018 Apr; 49(1):38. PubMed ID: 29690928
[TBL] [Abstract][Full Text] [Related]
22. Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.
DeClue AE; Axiak-Bechtel SM; Zhang Y; Saha S; Zhang L; Tung DD; Bryan JN
BMC Vet Res; 2018 Apr; 14(1):119. PubMed ID: 29606140
[TBL] [Abstract][Full Text] [Related]
23. Bacteriolytic therapy of experimental pancreatic carcinoma.
Maletzki C; Gock M; Klier U; Klar E; Linnebacher M
World J Gastroenterol; 2010 Jul; 16(28):3546-52. PubMed ID: 20653063
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors.
Krick EL; Sorenmo KU; Rankin SC; Cheong I; Kobrin B; Thornton K; Kinzler KW; Vogelstein B; Zhou S; Diaz LA
Am J Vet Res; 2012 Jan; 73(1):112-8. PubMed ID: 22204296
[TBL] [Abstract][Full Text] [Related]
25. Clostridium to treat cancer: dream or reality?
Theys J; Lambin P
Ann Transl Med; 2015 May; 3(Suppl 1):S21. PubMed ID: 26046067
[TBL] [Abstract][Full Text] [Related]
26. Bacteriolytic therapy with Clostridium ghonii for experimental solid tumors.
Wang Y; Liu Y; Zhu H; Wang D; Wang S; Xu X; Yu N; Feng J; Zou J; Wang X; Xing Y; Zhang W
Biochem Biophys Res Commun; 2022 Dec; 634():114-121. PubMed ID: 36242917
[TBL] [Abstract][Full Text] [Related]
27. Methods and Techniques to Facilitate the Development of
Dailey KM; Jacobson RI; Johnson PR; Woolery TJ; Kim J; Jansen RJ; Mallik S; Brooks AE
Front Microbiol; 2021; 12():624618. PubMed ID: 33854487
[TBL] [Abstract][Full Text] [Related]
28. Functional antibodies produced by oncolytic clostridia.
Groot AJ; Mengesha A; van der Wall E; van Diest PJ; Theys J; Vooijs M
Biochem Biophys Res Commun; 2007 Dec; 364(4):985-9. PubMed ID: 17971292
[TBL] [Abstract][Full Text] [Related]
29. Bacterial proteolytic activity improves drug delivery in tumors in a size, pharmacokinetic, and binding affinity dependent manner - A mechanistic understanding.
Shirai H; Tsukada K
J Control Release; 2020 May; 321():348-362. PubMed ID: 32061790
[TBL] [Abstract][Full Text] [Related]
30. A bacterial protein enhances the release and efficacy of liposomal cancer drugs.
Cheong I; Huang X; Bettegowda C; Diaz LA; Kinzler KW; Zhou S; Vogelstein B
Science; 2006 Nov; 314(5803):1308-11. PubMed ID: 17124324
[TBL] [Abstract][Full Text] [Related]
31. Spore coat architecture of Clostridium novyi NT spores.
Plomp M; McCaffery JM; Cheong I; Huang X; Bettegowda C; Kinzler KW; Zhou S; Vogelstein B; Malkin AJ
J Bacteriol; 2007 Sep; 189(17):6457-68. PubMed ID: 17586633
[TBL] [Abstract][Full Text] [Related]
32. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria.
Bettegowda C; Dang LH; Abrams R; Huso DL; Dillehay L; Cheong I; Agrawal N; Borzillary S; McCaffery JM; Watson EL; Lin KS; Bunz F; Baidoo K; Pomper MG; Kinzler KW; Vogelstein B; Zhou S
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15083-8. PubMed ID: 14657371
[TBL] [Abstract][Full Text] [Related]
33. Clostridium novyi exhibits antitumor effect in mice transplanted with H22 hepatocarcinoma by down-regulation of hypoxia-inducible factor-1α.
Huang XJ; Yang Y; Deng ZM; Kuang Y; Shi H; Li WY; Li MY
J Biol Regul Homeost Agents; 2020; 34(6):2159-2164. PubMed ID: 33225677
[No Abstract] [Full Text] [Related]
34. Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery.
Theys J; Patterson AV; Mowday AM
Mol Diagn Ther; 2024 Mar; 28(2):141-151. PubMed ID: 38302842
[TBL] [Abstract][Full Text] [Related]
35. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer.
Yasuda H
Nitric Oxide; 2008 Sep; 19(2):205-16. PubMed ID: 18503779
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific gene delivery using genetically engineered bacteria.
Theys J; Barbé S; Landuyt W; Nuyts S; Van Mellaert L; Wouters B; Anné J; Lambin P
Curr Gene Ther; 2003 Jun; 3(3):207-21. PubMed ID: 12762480
[TBL] [Abstract][Full Text] [Related]
37. Discodermolide analogues as the chemical component of combination bacteriolytic therapy.
Smith AB; Freeze BS; LaMarche MJ; Sager J; Kinzler KW; Vogelstein B
Bioorg Med Chem Lett; 2005 Aug; 15(15):3623-6. PubMed ID: 15979874
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic and toxicologic evaluation of C. novyi-NT spores.
Diaz LA; Cheong I; Foss CA; Zhang X; Peters BA; Agrawal N; Bettegowda C; Karim B; Liu G; Khan K; Huang X; Kohli M; Dang LH; Hwang P; Vogelstein A; Garrett-Mayer E; Kobrin B; Pomper M; Zhou S; Kinzler KW; Vogelstein B; Huso DL
Toxicol Sci; 2005 Dec; 88(2):562-75. PubMed ID: 16162850
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral Clostridium novyi as a potential treatment for solid necrotic brain tumors.
Zwagerman NT; Friedlander RM; Monaco EA
Neurosurgery; 2014 Dec; 75(6):N17-8. PubMed ID: 25406624
[No Abstract] [Full Text] [Related]
40. Infectious necrotic hepatitis caused by Clostridium novyi type B in a horse: case report and review of the literature.
Nyaoke AC; Navarro MA; Beingesser J; Uzal FA
J Vet Diagn Invest; 2018 Mar; 30(2):294-299. PubMed ID: 29224513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
